Terumo Blood and Cell Technologies (hereinafter referred to as “Terumo BCT”) and Shenzhen Eureka Biotechnology Co., Limited (hereinafter referred to as “EurekaBio”) announced their strategic partnership on March 17, 2023. The two parties will collaborate on establishing a cell therapy process development platform laboratory. By leveraging their complementary advantages and fostering joint innovation, both parties aim to integrate automation technology and conduct process development. Their collective efforts will focus on delivering more efficient automated production solutions for the global cell therapy industry, improving the production efficiency of cell products, and promoting the development of the cell therapy industry.
The process development platform laboratory will be equipped with Terumo BCT’s cutting-edge technology, which includes advanced cell product manufacturing equipment such as the Quantum Flex Cell Expansion System, TSCD®-Q Sterile Tubing Welder, and Finia® Fill and Finish System. Quantum Flex is a cutting-edge cell expansion platform recently launched by Terumo. It is a fully automated and functionally closed cell expansion system, making it one of the pioneering systems available in the market that supports the commercial development of cell therapy from process development to manufacturing. This system facilitates the expansion of suspension cells, adherent cells, or exosomes in a low-shear stress environment. Moreover, it offers flexible applications for the expansion of both autologous and allogeneic therapeutic products. The Finia system was launched in 2020 and is capable of fully automating the filling process of cell therapy formulations.
As a leading domestic enterprise specializing in cell preparation automation equipment, EurekaBio also offers independently developed technologies, such as the CellSep® PRO Fully Automated Closed Cell Processing System and CellSep® MAX Fully Closed and Automated Continuous Flow Cell Processing System. The two parties aim to provide efficient and flexible end-to-end optimization solutions for biopharmaceutical companies and research institutions in the field of cell therapy both domestically and internationally.
Li Lei, Vice President for Asia Pacific at Terumo BCT, expressed that “Collaborations play a pivotal role in expediting process improvements and commercialization of therapies within the cell therapy sector. The strategic partnership with EurekaBio allows us to offer comprehensive and flexible automation solutions to academic and early-stage customers. Our high-quality technology platform and services, together with EurekaBio’s expertise in process optimization, enable us to meet our customers at various stages of their product development and develop a scalable strategy for the future”.
Mr. Ma Mo, CEO of EurekaBio, stated that “We are thrilled to partner with Terumo BCT and jointly develop cell preparation processes. Terumo BCT, as a global provider of comprehensive solutions, has a strong foundation in the field of cell therapy. By combining our strengths through this collaboration, we can deliver more flexible and innovative solutions to customers, effectively meeting their automation needs in cell preparation processes. We strongly believe that this collaboration holds immense value for the rapid development of the cell therapy industry”.
Terumo Blood and Cell Technologies is a company dedicated to providing medical technology product services. We specialize in providing global comprehensive solutions in the fields of blood components, therapeutic apheresis, and cell therapy technologies. Our portfolio includes a range of automation production equipment for cell therapy, such as the Quantum Flex Cell Expansion System, Finia® Fill and Finish System, and TSCD®-Q Sterile Tubing Welder. Through our products, technologies, and services, we empower customers to collect and prepare blood and cells to effectively treat challenging diseases and conditions. Our worldwide team of dedicated employees shares a belief in the untapped potential of blood and cells to bring even greater benefits to patients in the future.
EurekaBio is a company dedicated to the research and development of core technologies and processes in CGT.
Through the integration of automation technology and biotechnology, EurekaBio has independently developed two fully closed and automated cell processing systems, CellSep® PRO and CellSep® MAX. These systems assist in upgrading cell therapy processes from manual preparation to automated and standardized production. The CellSep® PRO system has already been adopted by numerous cell therapy companies, with customer products including CAR-T, TCR-T, CAR-NK, TIL, stem cells, and other cellular therapies. Approximately 30 companies have incorporated the CellSep® PRO system into their processes for IND application, Phase I, and Phase II clinical trials.
To address the challenges in lentiviral vector production, EurekaBio has innovatively developed the EuLV® system and associated scale-up processes This system, based on stable producer cell lines, enables large-scale production of lentiviral vectors. It effectively addresses the technical bottleneck associated with scaling up lentiviral vector production, leading to significant improvements in production efficiency and consistency, and cost reduction.
+86-0755-86562586
.jpg)